Morgan Stanley
CNTX icon

Morgan Stanley’s Context Therapeutics CNTX Stock Holding History

Morgan Stanley’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.8K Buy
+9,077
New +$21.2K ﹤0.01% 6661
2025
Q3 		– Sell
-3,500
Closed -$2.29K – 8198
2025
Q2 		$2.29K Buy
3,500
+3,400
+3,400% +$2.44K ﹤0.01% 7199
2025
Q1 		$61 Sell
100
-127
-56% -$111 ﹤0.01% 7661
2024
Q4 		$238 Buy
+227
New +$393 ﹤0.01% 7397
2022
Q4 		– Sell
-17,057
Closed -$19K – 7902
2022
Q3 		$19K Buy
17,057
+7,057
+71% +$12.7K ﹤0.01% 6816
2022
Q2 		$21K Hold
10,000
– – ﹤0.01% 6953
2022
Q1 		$22K Buy
10,000
+5,000
+100% +$10.5K ﹤0.01% 7101
2021
Q4 		$13K Buy
+5,000
New +$24.9K ﹤0.01% 7370

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley's CNTX Position: Q1 2026 in Review

Morgan Stanley opened a new position in Context Therapeutics (CNTX) in Q1 2026: 9,077 shares worth $23.8K. The stake represents ﹤0.01% of the portfolio and ranks #6661 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in CNTX as recently as Q2 2025.

Morgan Stanley first reported a position in CNTX in Q4 2021 and has held it in 8 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Morgan Stanley held 9,077 shares of Context Therapeutics worth $23.8K as of Q1 2026.
  • Context Therapeutics was a new Morgan Stanley position in Q1 2026.
  • Context Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6661 holding.
  • Morgan Stanley first reported a position in Context Therapeutics in Q4 2021 and has held it in 8 quarters since.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.